Provided by Tiger Trade Technology Pte. Ltd.

Werewolf Therapeutics, Inc.

0.7808
-0.0823-9.54%
Post-market: 0.79000.0092+1.18%19:36 EDT
Volume:375.90K
Turnover:297.30K
Market Cap:37.90M
PE:-0.48
High:0.8400
Open:0.8400
Low:0.7650
Close:0.8631
52wk High:2.38
52wk Low:0.5301
Shares:48.54M
Float Shares:35.00M
Volume Ratio:1.80
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6177
EPS(LYR):-1.6273
ROE:-122.43%
ROA:-40.75%
PB:1.28
PE(LYR):-0.48

Loading ...

10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Common Shares

Reuters
·
Nov 26, 2025

Werewolf Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Nov 19, 2025

Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 18, 2025

MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 18, 2025

10% Owner Ansbert Gadicke Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 18, 2025

Director Luke Evnin Reports Sale of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 13, 2025

MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 13, 2025

10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Common Shares

Reuters
·
Nov 13, 2025

Werewolf Therapeutics Unveils Tumor-Selective INDUKINE Data at SITC 2025

Reuters
·
Nov 07, 2025

Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 07, 2025

MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 07, 2025

10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 07, 2025

Wedbush Halves Price Target on Werewolf Therapeutics to $3 From $6, Keeps Outperform Rating

MT Newswires Live
·
Nov 05, 2025

Werewolf Therapeutics reports Q3 EPS (36c), consensus (38c)

TIPRANKS
·
Nov 04, 2025

Werewolf Therapeutics Q3 EPS $(0.36) Beats $(0.39) Estimate

Benzinga
·
Nov 04, 2025

Werewolf Therapeutics Reports Q3 2025 Results and Plans Key Trial Updates

Reuters
·
Nov 04, 2025

MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Common Shares

Reuters
·
Nov 04, 2025

10% Owner Ansbert Gadicke Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 04, 2025

Werewolf Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Oct 30, 2025